# OnCo record nct05785741 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05785741/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05785741", "NCT05785741" ;
  schema:name "A Study of DB-1310 in Advanced/Metastatic Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Trastuzumab, Osimertinib and Capecitabine in advanced solid tumours, run by DualityBio Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05785741/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05785741> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-08-17" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/dualitybio/> .